Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.54 |
| ▸ | RAB9A | P51151 | 13/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.52 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424616 | 0.98 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TSHRS1PR1 | |
| SCHEMBL14108403 | 0.93 | MLLT1 (0.47) | NPC1RAB9ASMN1; SMN2TSHRS1PR1 | |
| Hydrochloric Acid SCHEMBL28847292 | 0.92 | MLLT1 (0.46) | NPC1RAB9ASMN1; SMN2TSHRS1PR1 | |
| SCHEMBL27028220 | 0.87 | CNR2 (0.47) | NPC1RAB9ASMN1; SMN2TSHRS1PR1 | |
| Hydrochloric Acid SCHEMBL693291 | 0.84 | SMYD3 (0.59) | NPC1RAB9AS1PR1MLLT1 | |
| SCHEMBL3367312 | 0.84 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2TSHRS1PR1 | |
| SCHEMBL31411804 | 0.81 | CHRNA4 (0.40) | NPC1RAB9ASMN1; SMN2TSHRS1PR1 | |
| SCHEMBL31411872 | 0.81 | CHRNA4 (0.40) | NPC1RAB9ASMN1; SMN2TSHRS1PR1 | |
| SCHEMBL30436829 | 0.80 | GABRA1 (0.39) | NPC1RAB9ASMN1; SMN2TSHRKMT2A | |
| SCHEMBL31411850 | 0.78 | CD38 (0.43) | NPC1RAB9ASMN1; SMN2TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | NPC1 3360/4885RAB9A 949/4885SMN1; SMN2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.